October 14, 2025 — Leads & Copy — Sunshine Biopharma (NASDAQ:SBFM) is implementing a flywheel model for biotech, focusing on lean, step-by-step growth rather than rapid, energy-intensive expansion.
The company’s Nora Pharma arm has established a catalog of therapeutic products in Canada, generating real revenue through launches like gabapentin, establishing credibility and cash flow.
Sunshine Biopharma has expanded into biosimilars with NIOPEG®, signaling its capability to handle biologics and aim for higher-margin opportunities.
Sunshine has bolstered its balance sheet by investing $5 million in a digital treasury asset, designed to support future growth and alleviate dilution pressure.
Aegis Capital has reiterated a BUY rating on Sunshine Biopharma, with a $7.00 price target, citing the company’s balanced progress.
In Q1, Sunshine Biopharma reported $8.9 million in revenue, an 18% increase year-over-year, with a gross profit of $2.73 million and a net loss of $1.18 million. Q2 revenue rose to $9.41 million.
Sunshine’s K1.1 mRNA therapy shows promise in preclinical models for liver cancer, while its antiviral program with the University of Arizona is developing protease inhibitors with antiviral activity in virus-infected models.
Sunshine Biopharma currently has 72 generic prescription drugs on the market in Canada and plans to launch more than 12 additional drugs in the remainder of 2025. The company is also developing K1.1 mRNA, targeted for liver cancer, and a PLpro protease inhibitor for SARS Coronavirus infections.
For more information about this content, please contact: info@hawkpointmedia.com
Source: Sunshine Biopharma Inc.
